Adds to existing law to establish cost-sharing requirements for health benefit plans.
House Bill 219 would add a new section to Idaho insurance law governing how insurers calculate an enrollee’s cost-sharing obligations under health benefit plans. The bill requires insurers, when determining whether a member has met a copayment, coinsurance, deductible, or annual cost-sharing limit for a covered health care service, to count amounts paid either by the enrollee or paid on the enrollee’s behalf by another party. The bill defines “health care service” broadly to include items or services used to prevent, alleviate, cure, or heal illness, injury, or physical disability, including prescription drugs.
The bill applies to health benefit plans entered into, amended, extended, or renewed on or after January 1, 2026. It also creates a limited exception for prescription drugs when a medically appropriate generic equivalent exists and the patient’s doctor indicates that the generic is appropriate. The Department of Insurance is authorized to adopt rules, subject to legislative approval, to implement the new section. The act is declared an emergency and would take effect July 1, 2025.
This bill would amend Chapter 3, Title 41 of the Idaho Code by adding Section 41-351, creating a new statewide rule for how insurers must credit third-party payments toward a patient’s cost-sharing obligations. In practice, it affects health insurers, health benefit plans, and enrollees who receive assistance from family members, charities, coupon programs, or other third parties in paying out-of-pocket medical costs. It may also affect how deductibles and annual out-of-pocket maximums are administered for covered services, especially prescription drugs, beginning with plans renewed or issued on or after January 1, 2026.
Based on the bill text and the absence of recorded committee testimony or votes in the provided materials, the overall sentiment appears procedural and policy-focused rather than overtly contentious. The bill is presented as a committee measure from the House Health and Welfare Committee, suggesting institutional support for the proposal. No recorded opposition, amendments, or divided vote history is included in the materials provided.
The main policy issue is whether insurers should be required to count third-party payments toward a patient’s cost-sharing limits, which can reduce out-of-pocket exposure for enrollees but may also affect insurer cost-management practices. The prescription drug exception is another potential point of contention, because it limits the rule where a generic equivalent is available and medically appropriate, preserving some insurer discretion and potentially affecting patients who rely on manufacturer assistance or other payment support. The Department of Insurance rulemaking authority could also draw attention from stakeholders concerned about how the new requirements will be implemented.